In vitro inhibition of hematopoiesis in a patient with systemic sclerosis treated with D-penicillamine

Journal of Rheumatology

Volumn 26, Issue 11, 1999, Pages 2493-2495

  Katayama, Yoshio ^a   Kohriyama, Kenji ^b   Matsui, Toshimitsu ^b  

^a KOBE CITY MEDICAL CENTER WEST HOSPITAL   (Japan)

^b NONE

Author keywords

D Penicillamine; Inhibition of hematopoiesis; Systemic sclerosis

Indexed keywords

CORTICOSTEROID; PENICILLAMINE;

AGED; ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; CASE REPORT; CLINICAL FEATURE; CORTICOSTEROID THERAPY; FEMALE; HEMATOPOIESIS; HUMAN; HUMAN CELL; LEUKOPENIA; PRIORITY JOURNAL; SYSTEMIC SCLEROSIS; THROMBOCYTOPENIA;

AGED; ANEMIA; ANTIRHEUMATIC AGENTS; COLONY-FORMING UNITS ASSAY; FEMALE; HEMATOPOIESIS; HUMANS; PENICILLAMINE; SCLERODERMA, SYSTEMIC;

EID: 0032723807     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Multicenter trial group. Controlled trial of D-penicillamine in severe rheumatoid arthritis. Lancet 1973;1:275-80.
2. Steen VD, Medsger TA Jr, Rodnan GP. D-penicillamine therapy in progressive systemic sclerosis (scleroderma): a retrospective analysis. Ann Intern Med 1982;97:652-9.
3. Day AT, Golding JR, Lee PN, Butterworth AD. Penicillamine in rheumatoid disease: a long-term study. BMJ 1974;1:180-3.
4. Weiss AS, Markenson JA, Weiss MS, Kammerer WH. Toxicity of D-penicillamine in rheumatoid arthritis. A report of 63 patients including two with aplastic anemia and one with the nephrotic syndrome. Am J Med 1978;64:114-20.
5. Kay AG. Myelotoxicity of D-penicillamine. Ann Rheum Dis 1979;38:232-6.
6. Sullivan AL, Burakoff R, Weintraub LR. Sideroblastic anemia associated with penicillamine therapy. Arch Intern Med 1981;141:1713-4.
7. Thomas D, Gallus AS, Brooks PM, Tampi R, Geddes R, Hill W. Thrombokinetics in patients with rheumatoid arthritis treated with D-penicillamine. Ann Rheum Dis 1984;43:402-6.
8. Steen VD, Blair S, Medsger TA Jr. The toxicity of D-penicillamine in systemic sclerosis. Ann Intern Med 1986;104:699-705.
9. Fishel B, Tishler M, Caspi D, Yaron M. Fatal aplastic anaemia and liver toxicity caused by D-penicillamine treatment of rheumatoid arthritis. Ann Rheum Dis 1989;48:609-10.
10. Vitali C, Bombardieri S, Moutsopoulos HM, et al. Preliminary criteria for the classification of Sjögren's syndrome. Arthritis Rheum 1993;36:340-7.
11. Subcommittee for scleroderma criteria of the American rheumatism Association diagnostic and therapeutic criteria committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980;23:581-90.
12. Katayama Y, Mahmut N, Takimoto H, et al. Hematopoietic progenitor cells from allogeneic bone marrow transplant donors circulate in the very early post-transplant period. Bone Marrow Transplant 1999;23;659-65.
13. Baum J. The use of penicillamine in the treatment of rheumatoid arthritis and scleroderma. Scand J Rheumatol 1979; Suppl 28:65-70.
14. Saetre R, Rabenstein DL. Determination of penicillamine in blood and urine by high performance liquid chromatography. Anal Chem 1978;50:278-80.
15. Hamilton JA, Williams N. In vitro inhibition of myelopoiesis by gold salts and D-penicillamine. J Rheumatol 1985;12:892-6.